Translational Drug Development (TD2)
Antonio Gutierrez-Kilp is a skilled data specialist currently employed at Translational Drug Development (TD2) since July 2022. Prior experience includes roles as a flow cytometrist at Sonora Quest Laboratories/Laboratory Sciences of Arizona, where Antonio managed high-volume testing for leukemia/lymphoma and COVID-19 sample processing as a medical laboratory technician. Additionally, Antonio worked as a laboratory technician at Celebration Stem Cell Center, focusing on the isolation and cryopreservation of stem cells. An internship at the Tissue Engineering and Regenerative Medicine Lab involved research on environmental contaminants and hormone therapy effects on wound healing. Antonio also served as a laboratory teaching assistant at Northern Arizona University, contributing to anatomy and physiology as well as microbiology labs. Antonio holds a Bachelor of Science degree in Biology from Northern Arizona University.
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.